CD274 and neoplasm: We found no significant difference in measured PD-L1 tumor expression between the 22C3, the most common assay type, and the 28–8 assay, in this observational study of PD-L1 testing patterns for patients with metastatic or recurrent NSCLC at US oncology practices.